Expression of PD-L1 among 34 human lymphoma cell lines
| Cell line | Lymphoma subtype | PD-L1 | PD-L2 |
|---|---|---|---|
| B cell | |||
| Daudi | Burkitt | − | − |
| Raji | Burkitt | − | − |
| Ramos | Burkitt | − | − |
| BJA-B | Burkitt | − | − |
| MC116 | Burkitt | − | − |
| NU-DHL-1 | DLBCL (GCB) | − | − |
| OCI-Ly-2 | DLBCL (GCB) | − | − |
| OCI-Ly-7 | DLBCL (GCB) | − | − |
| OCI-Ly-19 | DLBCL (GCB) | − | − |
| SU-DHL-4 | DLBCL (GCB) | − | − |
| SU-DHL-6 | DLBCL (GCB) | − | − |
| SU-DHL-2 | DLBCL (ABC) | − | − |
| U2932 | DLBCL (ABC) | − | − |
| OCI-Ly-3 | DLBCL (ABC) | − | − |
| OCI-Ly-10 | DLBCL (ABC) | ++ | − |
| HBL-1 | DLBCL (ABC) | + | − |
| RC-K8 | DLBCL (NF-κB+) | + | − |
| SU-DHL-5 | DLBCL | − | − |
| SU-DHL-7 | DLBCL | − | − |
| SU-DHL-8 | DLBCL | − | − |
| SU-DHL-9 | DLBCL | − | − |
| SU-DHL-10 | DLBCL | − | − |
| SU-DHL-16 | DLBCL | − | − |
| USC-DHL-1 | DLBCL | − | − |
| Granta-519 | Mantle cell | − | − |
| JeKo-1 | Mantle cell | − | − |
| REC-1 | Mantle cell | − | − |
| BCBL-1 | 1° effusion | − | − |
| T cell | |||
| Karpas 299 | ALCL | ++ | − |
| SU-DHL-1 | ALCL | ++ | − |
| SUP-M2 | ALCL | ++ | − |
| DEL | ALCL | + | − |
| Jurkat | T-ALL | + | − |
| Hut78 | Sezary syndrome | − | − |
NOTE: Expression of PD-L1 and PD-L2 was measured by flow cytometry. “++” indicates ≥2 log MFI above isotype control; “+” indicates < 2 logs MFI above control.
Abbreviation: T-ALL, precursor T acute lymphoblastic leukemia.